Detalhe da pesquisa
1.
Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study.
BMC Cancer
; 23(1): 663, 2023 Jul 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37452287
2.
Systemic treatment of metastatic squamous cell carcinoma of the head and neck: proposal for management changes.
Curr Opin Oncol
; 33(3): 160-167, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33782359
3.
The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours.
Acta Oncol
; 60(12): 1597-1603, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34549686
4.
Long-term prognosis of septic shock in cancer patients.
Support Care Cancer
; 28(3): 1325-1333, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31243586
5.
Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.
Ann Rheum Dis
; 77(3): 393-398, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29146737
6.
Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: case report of an unexpected response.
BMC Cancer
; 17(1): 323, 2017 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28494780
7.
Prognostic factors for cancer patient admitted to a medical intensive care unit.
Acta Oncol
; 59(4): 458-461, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31948319
8.
Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives.
Immunotherapy
; 16(3): 187-197, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38126161
9.
Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumors.
Oncoimmunology
; 12(1): 2150472, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36545254
10.
Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study.
RMD Open
; 9(4)2023 11 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38030233
11.
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.
J Clin Oncol
; 41(12): 2166-2180, 2023 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36473143
12.
Management of 80 sinonasal undifferentiated carcinomas. Retrospective multicentre study of the French Network of Rare Head and Neck Cancers (REFCOR).
Eur J Surg Oncol
; 49(12): 107108, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37866154
13.
Pulmonary arterial hypertension due to an intratumoral shunt: an unexpected side effect of sunitinib.
Future Oncol
; 13(14): 1219-1221, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28606002
14.
Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non-small cell lung cancer: A retrospective study.
Thorac Cancer
; 13(9): 1391-1400, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35434866
15.
Colitis presenting 5 months after the final dose of anti-PD-1: long-term monitoring is warranted after adjuvant therapy.
Immunotherapy
; 13(9): 741-744, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33906378
16.
Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review.
Eur J Cancer
; 158: 47-62, 2021 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34655837
17.
Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
Cancer Med
; 10(12): 3952-3963, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34080776
18.
Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck.
Eur J Cancer
; 157: 190-197, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34536943
19.
Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial.
J Immunother Cancer
; 9(10)2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34663640
20.
Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events.
Eur J Cancer
; 157: 474-484, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34649118